ETON

Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.

Wall Street analysts forecast ETON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ETON is 35.00 USD with a low forecast of 35.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Eton Pharmaceuticals Inc revenue for the last quarter amounts to 22.46M USD, increased 117.54 % YoY.

Eton Pharmaceuticals Inc. EPS for the last quarter amounts to -0.07 USD, decreased -450.00 % YoY.

Eton Pharmaceuticals Inc (ETON) has 31 emplpoyees as of December 16 2025.

Today ETON has the market capitalization of 427.74M USD.